The Online Investor
Home
Dividends
25 Safe Dividends
Stock Splits
Mergers & Acquisitions
Business Services/Equipment M&A

Construction M&A
   General Contractors & Builders M&A
Consumer Goods M&A
   Sporting Goods & Activities M&A
   Office Supplies M&A
   Food & Beverage M&A
   Beverages & Wineries M&A
   Cigarettes & Tobacco M&A
   Marijuana Stocks M&A
   Apparel Stores M&A
   Department Stores M&A
   Grocery & Drug Stores M&A
   Electronics Stores M&A
   Home Improvement Stores M&A
   Home Furnishing Stores M&A
   Auto Dealerships M&A
   Specialty Retail M&A
Consumer Services M&A
   Education & Training Services M&A
Energy M&A
   Oil & Gas Refining & Marketing M&A
   Oil & Gas Exploration & Production M&A
   Oil & Gas Equipment & Services M&A
Financial M&A
   Banking & Savings M&A
   Investment Brokerages M&A
   Investment Companies & Venture Capital M&A
   Asset Management M&A
   Credit Services & Lending M&A
   Life & Health Insurance M&A
   Insurance Brokers M&A
Healthcare M&A
   Drugs & Pharmaceuticals M&A
   Biotechnology M&A
   Diagnostics M&A
   Medical Instruments & Supplies M&A
   Hospital & Medical Practitioners M&A
Industrial M&A
   Chemicals M&A
   Specialty Chemicals M&A
   Defense M&A
   Aerospace & Defense M&A
   Construction Materials & Machinery M&A
   Industrial Machinery & Equipment M&A
Manufacturing M&A
   Home Furnishings & Furniture M&A
   Auto Manufacturers M&A
   Auto Parts M&A
   Textiles & Apparel M&A
Materials M&A
   Agricultural Chemicals M&A
   Rubber & Plastics M&A
   Paper & Forest Products M&A
   Packaging & Containers M&A
   Agriculture & Farm Products M&A
Media M&A
   Advertising M&A
   Television & Radio M&A
   Publishing & Printing M&A
Metals & Mining M&A
   Precious Metals M&A
   Non-Precious Metals & Non-Metallic Mining M&A
   Metals Fabrication & Products M&A
Real Estate M&A
   REITs M&A
Technology M&A
   Electronic Equipment & Products M&A
   3D Printing Stocks M&A
   Computers M&A
   Computer Peripherals M&A
   Application Software M&A
   Semiconductors M&A
   Information Technology Services M&A
Transportation M&A
   Air Services Other M&A
   Airlines M&A
   Trucking M&A
   Shipping M&A
   Railroads M&A
Travel & Entertainment M&A
   Hotels, Lodging, Restaurants & Travel M&A
   Entertainment M&A
Utilities M&A
   Waste Management M&A
   Communications Services M&A
   Electric Utilities M&A
   Gas Utilities M&A
   Water Utilities M&A
Mega Mergers
Daily M&A
Contrarian Outlook
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com
Stock Buybacks
IPOs
Secondary Offerings
Top 20 Large Caps
Top 20 Biggest ETFs
Insider Buying
Top 25 Low PE Ratios
Analyst Actions
25 Top Analyst Picks
Articles
CAGR Calculator
Dunnan On Dollars
10 Pot Stocks
ETF Center
Knowledge Center
Retirement Center
Advertising Opportunities
Privacy Policy
Disclaimer Statement
Biotechnology M&A image Biotechnology M&A » By The Online Investor Staff, updated Thu., May. 9, 3:01 AM Recent mergers and acquisitions in the Biotechnology M&A category.

This Slide: #37 of 83

Slide #37. Oxygen Biotherapeutics — Phyxius Pharma Assets

Acquirer: Oxygen Biotherapeutics (OXBT)
Acquiree: Phyxius Pharma Assets
Details: Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT) a developer of oxygen-carrying therapeutics, today announced the closing of its acquisition of certain assets of Phyxius Pharma, a privately-held biopharmaceutical company focused on the development and near-term commercialization of levosimendan to prevent and treat cardiac surgery patients at risk for developing low cardiac output syndrome (LCOS), a significant unmet medical need. Pursuant to the previously announced Purchase Agreement, Oxygen Biotherapeutics acquired the exclusive rights to develop and commercialize levosimendan in North America, and will welcome three key Phyxius Pharma executives into its management team.

Oxygen Biotherapeutics is engaged in developing biotechnology products with a focus on oxygen delivery to specific target tissues. Co. is developing Oxycyte®, a systemic perfluorocarbon product for use in situations of acute ischemia, which is in clinical trial for the treatment of traumatic brain injury. Co. is also developing its topical products: Dermacyte® line of topical cosmetic products for skin health and other cosmetic benefits; and Wundecyte™ gel developed under a contract agreement with a lab in Virginia that is designed to be used as a wound-healing gel. Co. also has under development Vitavent™, an oxygen exchange fluid for facilitating the treatment of lung conditions.

Open the OXBT Page at The Online Investor »

OXBT — Key Stats (updated Tue., Sep. 23, 10:22 AM)
Company Name:  Tenax Therapeutics Inc
Website:  www.oxygenbiotherapeutics.com
Sector:  Biotechnology
 

Open the OXBT Page at The Online Investor (in a new window) »
May 9, 2024  •  3:01 AM Eastern
OXBT — Current Quote
Quotes delayed 20 minutes

Email EnvelopeFree OXBT Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts
Avg. Broker Rec.

Strong Buy (4.00 out of 4)
100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Biotechnology M&A - Slide 37 of 83 | www.TheOnlineInvestor.com | Copyright © 1998 - 2024, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.